Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. Catalent, Inc.
  6. Summary
    CTLT   US1488061029

CATALENT, INC.

(CTLT)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
06/10/2021 06/11/2021 06/14/2021 06/15/2021 06/16/2021 Date
108.87(c) 109.05(c) 109.58(c) 108.47(c) 109.01 Last
990 340 496 774 516 066 657 305 75 702 Volume
+1.46% +0.17% +0.49% -1.01% +0.50% Change
More quotes
Financials (USD)
Sales 2021 3 944 M - -
Net income 2021 507 M - -
Net Debt 2021 1 977 M - -
P/E ratio 2021 36,8x
Yield 2021 -
Sales 2022 4 340 M - -
Net income 2022 482 M - -
Net Debt 2022 1 761 M - -
P/E ratio 2022 40,8x
Yield 2022 -
Capitalization 18 477 M 18 477 M -
EV / Sales 2021 5,19x
EV / Sales 2022 4,66x
Nbr of Employees 13 900
Free-Float 99,4%
More Financials
Company
Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels. The Drug Delivery Solutions... 
Read more
Sector
Pharmaceuticals
Calendar
06/15Presentation
More about the company
Ratings of Catalent, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about CATALENT, INC.
06/04CATALENT, INC.  : to Present at the Biopharma CEO Investor Forum
BU
06/03MARKET CHATTER : AstraZeneca in Talks with US to Shift COVID-19 Vaccine Producti..
MT
06/02AstraZeneca in talks to shift COVID-19 vaccine production to Catalent factory..
RE
06/02AstraZeneca in talks to shift COVID-19 vaccine production to Catalent factory..
RE
05/28CATALENT, INC.  : to Present at the Jefferies Healthcare Conference and the Will..
BU
05/21CATALENT, INC.  : to Present at the UBS Global Healthcare Virtual Conference
BU
05/21AVECHO BIOTECHNOLOGY  : Completes Cannabidiol Soft Gel Product Design; Shares Ra..
MT
05/20CATALENT, INC.  : Change in Directors or Principal Officers, Financial Statement..
AQ
05/13CATALENT  : Publishes Second Annual Corporate Responsibility Report Highlighting..
BU
05/12CATALENT  : Tom Castellano (Form 8-K)
PU
05/12CATALENT  : Hofseth BioCare Announces Global Innovation Partnership with Catalen..
PU
05/11Animal-Health Company Zoetis Promotes CFO to Expanded Role
DJ
05/11CATALENT  : Names Thomas Castellano CFO
MT
05/11Catalent Promotes Executive to Succeed CFO, Who Will Depart for Zoetis
DJ
05/11Zoetis Promotes CFO to Group President, Brings in Catalent CFO
DJ
More news
News in other languages on CATALENT, INC.
04/29Moderna stellt 2022 drei Milliarden Corona-Impfdosen in Aussicht
04/07DGAP-HV : Fresenius Medical Care AG & Co. KGaA: -4-
04/07DGAP-HV : Fresenius Medical Care AG & Co. KGaA: -2-
04/07USA  : Biden, tutti gli adulti vaccinabili entro il 19/4
04/06MODERNA  : étend sa collaboration stratégique avec Catalent
More news
Analyst Recommendations on CATALENT, INC.
More recommendations
Stock Trading Strategies
CATALENT, INC. - 2020
The trend should continue
BUY
More Stock Trading Analysis
Analysis
Sanofi : Biden says will have enough COVID-19 vaccine for every U.S. adult by May
Chart CATALENT, INC.
Duration : Period :
Catalent, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CATALENT, INC.
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Average target price 136,70 $
Last Close Price 108,47 $
Spread / Highest target 30,9%
Spread / Average Target 26,0%
Spread / Lowest Target 13,4%
EPS Revisions
Managers and Directors
NameTitle
John R. Chiminski Chairman & Chief Executive Officer
Alessandro Maselli President & Chief Operating Officer
Thomas P. Castellano Chief Financial Officer & Senior Vice President
Kay Schmidt Senior Vice President-Technical Operations
Julien Meissonnier Chief Scientific Officer & Vice President
Sector and Competitors
1st jan.Capitalization (M$)
CATALENT, INC.4.23%18 477
JOHNSON & JOHNSON4.52%433 167
ROCHE HOLDING AG11.21%330 710
PFIZER, INC.7.55%221 613
NOVARTIS AG0.77%210 689
ABBVIE INC.8.10%204 582